DE69533623D1 - Verfahren zur unterstützung der diagnose der alzheimerschen krankheit durch messung der amyloid-beta-peptide(x groesser als oder gleich 41) und tau - Google Patents
Verfahren zur unterstützung der diagnose der alzheimerschen krankheit durch messung der amyloid-beta-peptide(x groesser als oder gleich 41) und tauInfo
- Publication number
- DE69533623D1 DE69533623D1 DE69533623T DE69533623T DE69533623D1 DE 69533623 D1 DE69533623 D1 DE 69533623D1 DE 69533623 T DE69533623 T DE 69533623T DE 69533623 T DE69533623 T DE 69533623T DE 69533623 D1 DE69533623 D1 DE 69533623D1
- Authority
- DE
- Germany
- Prior art keywords
- alzheimer
- diagnosis
- disease
- measuring
- tau
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 208000024827 Alzheimer disease Diseases 0.000 title abstract 3
- 238000003745 diagnosis Methods 0.000 title abstract 2
- 102000013455 Amyloid beta-Peptides Human genes 0.000 title 1
- 108010090849 Amyloid beta-Peptides Proteins 0.000 title 1
- 238000000034 method Methods 0.000 title 1
- 108090000765 processed proteins & peptides Proteins 0.000 abstract 2
- 238000012544 monitoring process Methods 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4711—Alzheimer's disease; Amyloid plaque core protein
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
- G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
- G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
- G01N2333/4701—Details
- G01N2333/4709—Amyloid plaque core protein
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2500/00—Screening for compounds of potential therapeutic value
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/28—Neurological disorders
- G01N2800/2814—Dementia; Cognitive disorders
- G01N2800/2821—Alzheimer
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S436/00—Chemistry: analytical and immunological testing
- Y10S436/811—Test for named disease, body condition or organ function
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Biomedical Technology (AREA)
- Organic Chemistry (AREA)
- Biochemistry (AREA)
- Medicinal Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Hematology (AREA)
- Neurology (AREA)
- Urology & Nephrology (AREA)
- Zoology (AREA)
- Food Science & Technology (AREA)
- Biotechnology (AREA)
- Cell Biology (AREA)
- Gastroenterology & Hepatology (AREA)
- Microbiology (AREA)
- Toxicology (AREA)
- Neurosurgery (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US08/339,141 US6114133A (en) | 1994-11-14 | 1994-11-14 | Methods for aiding in the diagnosis of Alzheimer's disease by measuring amyloid-β peptide (x-≧41) |
US41900895A | 1995-04-07 | 1995-04-07 | |
US419008 | 1995-04-07 | ||
PCT/US1995/014659 WO1996015452A1 (en) | 1994-11-14 | 1995-11-13 | METHODS FOR AIDING IN THE DIAGNOSIS OF ALZHEIMER'S DISEASE BY MEASURING AMYLOID-β PEPTIDE (X- ≥41) AND TAU |
US339141 | 1999-09-24 |
Publications (2)
Publication Number | Publication Date |
---|---|
DE69533623D1 true DE69533623D1 (de) | 2004-11-11 |
DE69533623T2 DE69533623T2 (de) | 2006-03-02 |
Family
ID=26991508
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DE69533623T Expired - Lifetime DE69533623T2 (de) | 1994-11-14 | 1995-11-13 | Verfahren zur unterstützung der diagnose der alzheimerschen krankheit durch messung der amyloid-beta-peptide(x groesser als oder gleich 41) und tau |
Country Status (11)
Country | Link |
---|---|
US (4) | US7427392B1 (de) |
EP (2) | EP1491889A3 (de) |
JP (2) | JP3634375B2 (de) |
AT (1) | ATE278957T1 (de) |
AU (1) | AU705907B2 (de) |
CA (1) | CA2205359C (de) |
DE (1) | DE69533623T2 (de) |
DK (1) | DK0792458T3 (de) |
ES (1) | ES2230551T3 (de) |
PT (1) | PT792458E (de) |
WO (1) | WO1996015452A1 (de) |
Families Citing this family (44)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6610493B1 (en) | 1993-06-17 | 2003-08-26 | Brigham And Women's Hospital | Screening compounds for the ability to alter the production of amyloid-β peptide |
US7427392B1 (en) | 1994-11-14 | 2008-09-23 | Elan Pharmaceuticals, Inc. | Methods for aiding in the diagnosis of alzheimer's disease by measuring amyloid-β peptide (x-≧41) and tau |
AU772151B2 (en) * | 1998-09-08 | 2004-04-08 | Innogenetics N.V. | Tau as a marker for early CNS damage |
EP1309341A2 (de) | 2000-07-07 | 2003-05-14 | Lars Lannfelt | Prävention und behandlung der alzheimer krankheit |
EP1975179A1 (de) * | 2001-12-26 | 2008-10-01 | Araclon Biotech, S.L. | Polyklonale Antikörper, Herstellungsverfahren und Verwendung |
US8360992B2 (en) | 2002-04-19 | 2013-01-29 | Sanofi-Aventis Deutschland Gmbh | Method and apparatus for penetrating tissue |
ES2246178B1 (es) * | 2003-05-08 | 2007-03-01 | Universidad De Zaragoza. | Uso de anticuerpos para el tratamiento de enfermedades amiloideas. |
SE0401601D0 (sv) * | 2004-06-21 | 2004-06-21 | Bioarctic Neuroscience Ab | Protofibril specific antibodies and uses thereof |
JP2008519988A (ja) * | 2004-11-12 | 2008-06-12 | ファイザー・インク | アミロイド−ベータペプチドを測定する方法 |
WO2007044094A1 (en) * | 2005-10-11 | 2007-04-19 | Blanchette Rockefeller Neurosciences Institute | Alzheimer's disease-specific alterations of the erk1/erk2 phosphorylation ratio as alzheimer's disease-specific molecular biomarkers (adsmb) |
EP2325209A3 (de) | 2006-03-23 | 2011-08-03 | BioArtic Neuroscience AB | Verbesserte protofibril selektive Antikörper und deren Verwendung |
EP1944314A1 (de) * | 2007-01-11 | 2008-07-16 | Philipps-Universität Marburg | Diagnose von Morbus Alzheimer und anderen Demenzerkrankungen |
DK2104682T3 (en) | 2007-01-11 | 2017-01-16 | Michael Bacher | DIAGNOSIS AND TREATMENT OF ALZHEIMER'S AND OTHER DEMENTIA DISEASES |
EP2578692B1 (de) | 2007-04-05 | 2016-06-08 | The J. David Gladstone Institutes | Mittel zur Reduktion der nervlichen Überreizung |
EP2009445A1 (de) * | 2007-06-29 | 2008-12-31 | Institut Pasteur | Verwendung von Einzeldomänen-Camelid-Antikörpern zur Entdeckung einer oligomeren Form eines Amyloid-Betapeptids und deren Anwendungen |
EP2020602A1 (de) * | 2007-08-02 | 2009-02-04 | Araclon Biotech | Hochempfindliche Immuntests und Kits zur Bestimmung biologisch interessanter Peptide und Proteine |
WO2010099199A1 (en) * | 2009-02-24 | 2010-09-02 | Gibbons Winton G | Detection of complexes of tau and amyloid |
US20100285108A1 (en) * | 2009-03-18 | 2010-11-11 | Ac Immune, S.A. | Method for therapeutic use |
UA107571C2 (xx) * | 2009-04-03 | 2015-01-26 | Фармацевтична композиція | |
EP2258398A1 (de) | 2009-05-26 | 2010-12-08 | Araclón Biotech, S. L. | Albumin/Amyloidpeptid-Konjugate und deren Verwendungen |
US20140302532A1 (en) | 2011-04-12 | 2014-10-09 | Quanterix Corporation | Methods of determining a treatment protocol for and/or a prognosis of a patient's recovery from a brain injury |
DK2579042T3 (da) | 2011-10-04 | 2014-07-21 | Affiris Ag | Fremgangsmåde til at påvise Aß-specifikke antistoffer i en biologisk prøve |
DE102011057021A1 (de) | 2011-12-23 | 2013-06-27 | Forschungszentrum Jülich GmbH | Verfahren zur selektiven Quantifizierung von A-Beta-Aggregaten |
JP5850374B2 (ja) | 2012-01-27 | 2016-02-03 | パナソニックヘルスケア株式会社 | アルツハイマー病の診断補助方法、及び診断システム |
AU2013243861A1 (en) | 2012-04-05 | 2014-10-23 | Ac Immune S.A. | Humanized Tau antibody |
HUE048780T2 (hu) | 2012-08-16 | 2020-09-28 | Ipierian Inc | Tauopátia kezelésére szolgáló módszerek |
US8980270B2 (en) | 2013-01-18 | 2015-03-17 | Ipierian, Inc. | Methods of treating a tauopathy |
ES2495266B8 (es) | 2013-02-13 | 2015-11-12 | Consejo Superior De Investigaciones Científicas (Csic) | Uso de igf-1 como reactivo de diagnóstico y/o pronóstico precoz de la enfermedad de alzheimer |
SG10201707855YA (en) | 2013-03-13 | 2017-10-30 | Prothena Biosciences Ltd | Tau immunotherapy |
CA2902910A1 (en) | 2013-03-15 | 2014-09-25 | Ac Immune S.A. | Anti-tau antibodies and methods of use |
KR20140128229A (ko) * | 2013-04-26 | 2014-11-05 | 한국과학기술연구원 | 체내 단백질 응집체의 용해를 이용한 단백질의 비정상적인 응집 또는 미스폴딩과 관련된 질환 또는 질병을 진단하는 혈액진단키트 |
WO2015020523A1 (en) | 2013-08-07 | 2015-02-12 | Stichting Vu-Vumc | Biomarkers for early diagnosis of alzheimer's disease |
CN105939722A (zh) | 2014-02-14 | 2016-09-14 | 伊皮埃里安股份有限公司 | Tau肽,抗Tau抗体,及其使用方法 |
KR101890978B1 (ko) | 2014-06-17 | 2018-08-24 | 서울대학교산학협력단 | 알츠하이머 질환 모델용 형질전환 돼지 및 이의 용도 |
CN106661103B (zh) | 2014-07-10 | 2020-11-03 | 生命北极神经科学公司 | 改进的Aβ初原纤维结合抗体 |
CA3022673A1 (en) | 2016-05-02 | 2017-11-09 | Prothena Biosciences Limited | Tau immunotherapy |
BR112018072394A2 (pt) * | 2016-05-02 | 2019-02-19 | Prothena Biosciences Limited | anticorpos que reconhecem a tau |
EP3452508A1 (de) | 2016-05-02 | 2019-03-13 | Prothena Biosciences Limited | Antikörper zur erkennung von tau |
IL270375B1 (en) | 2017-05-02 | 2024-08-01 | Prothena Biosciences Ltd | Antibodies that recognize tau |
AU2018355325A1 (en) | 2017-10-25 | 2020-05-07 | Ac Immune S.A. | Compositions of phosphorylated tau peptides and uses thereof |
WO2020098936A1 (fr) | 2018-11-14 | 2020-05-22 | Qynapse | Procede de determination d'un modele de prediction, procede de prediction de l'evolution d'un k-uplet de marqueurs mk et dispositif associe |
JOP20210211A1 (ar) | 2019-02-08 | 2023-01-30 | Janssen Pharmaceuticals Inc | طريقة إعطاء دواء آمنة للقاح ببتيد تاو المفسفر |
TW202100550A (zh) | 2019-03-03 | 2021-01-01 | 愛爾蘭商普羅帝納生物科學公司 | 識別tau之抗體 |
SG11202111770RA (en) | 2019-04-24 | 2021-11-29 | Janssen Pharmaceuticals Inc | Heterologous administration of tau vaccines |
Family Cites Families (33)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4271140A (en) | 1978-01-23 | 1981-06-02 | Baxter Travenol Laboratories, Inc. | Method and composition for double receptor, specific binding assays |
US4474892A (en) | 1983-02-16 | 1984-10-02 | Board Of Trustees Of The Leland Stanford Junior University | Two-site immunoassays using monoclonal antibodies of different classes or subclasses and test kits for performing same |
US4666829A (en) | 1985-05-15 | 1987-05-19 | University Of California | Polypeptide marker for Alzheimer's disease and its use for diagnosis |
JPS6267297A (ja) | 1985-09-18 | 1987-03-26 | Hitachi Ltd | ポンプの軸受潤滑装置 |
JPH0779702B2 (ja) | 1986-11-17 | 1995-08-30 | サイオス ノバ インコーポレイテッド | 組換えアルツハイマーアミロイドタンパク |
US5223482A (en) * | 1986-11-17 | 1993-06-29 | Scios Nova Inc. | Recombinant Alzheimer's protease inhibitory amyloid protein and method of use |
US5220013A (en) * | 1986-11-17 | 1993-06-15 | Scios Nova Inc. | DNA sequence useful for the detection of Alzheimer's disease |
US5547841A (en) * | 1987-10-08 | 1996-08-20 | The Mclean Hospital Corporation | In vitro method for screening for drugs that inhibit production or degradation of human A4-amyloid |
US5262332A (en) * | 1989-04-05 | 1993-11-16 | Brigham And Women's Hospital | Diagnostic method for Alzheimer's disease: examination of non-neural tissue |
AU5525090A (en) | 1989-04-14 | 1990-11-16 | Research Foundation For Mental Hygiene, Inc. | Monoclonal antibody to amyloid peptide |
WO1990012871A1 (en) | 1989-04-14 | 1990-11-01 | Research Foundation For Mental Hygiene, Inc. | Cerebrovascular amyloid protein-specific monoclonal antibody sv17-6e10 |
US5234814A (en) * | 1989-06-01 | 1993-08-10 | Du Pont Merck Pharmaceutical Company | Diagnostic assay for alzheimer's disease |
AU7121191A (en) | 1990-02-26 | 1991-10-10 | Albert Einstein College Of Medicine Of Yeshiva University | Diagnostic assay for alzheimer's disease |
US5213962A (en) * | 1990-04-24 | 1993-05-25 | The Regents Of The University Of California | Purification, detection and methods of use of protease Nexin-2 |
US5387742A (en) * | 1990-06-15 | 1995-02-07 | Scios Nova Inc. | Transgenic mice displaying the amyloid-forming pathology of alzheimer's disease |
JPH04252956A (ja) | 1991-01-29 | 1992-09-08 | Asahi Chem Ind Co Ltd | タンパク質の測定方法、試薬及びキット |
JPH04252955A (ja) | 1991-01-29 | 1992-09-08 | Asahi Chem Ind Co Ltd | 蛋白質の測定方法、試薬及びキット |
JPH04252954A (ja) | 1991-01-29 | 1992-09-08 | Asahi Chem Ind Co Ltd | タンパクの測定方法、試薬及びキット |
CA2127450C (en) | 1992-01-07 | 2007-04-17 | Samuel Wadsworth | Transgenic animal models for alzheimer's disease |
US5604102A (en) * | 1992-04-15 | 1997-02-18 | Athena Neurosciences, Inc. | Methods of screening for β-amyloid peptide production inhibitors |
US5837672A (en) | 1992-07-10 | 1998-11-17 | Athena Neurosciences, Inc. | Methods and compositions for the detection of soluble β-amyloid peptide |
US5766846A (en) | 1992-07-10 | 1998-06-16 | Athena Neurosciences | Methods of screening for compounds which inhibit soluble β-amyloid peptide production |
US6610493B1 (en) | 1993-06-17 | 2003-08-26 | Brigham And Women's Hospital | Screening compounds for the ability to alter the production of amyloid-β peptide |
DE69333144T2 (de) | 1992-10-26 | 2004-05-19 | Elan Pharmaceuticals, Inc., San Francisco | Verfahren zur Identifizierung von Hemmstoffe der Produktion des beta-Amyloidpeptids |
EP0683234B2 (de) | 1993-01-25 | 2007-06-06 | Takeda Chemical Industries, Ltd. | Antikörper gegen beta-amyloid oder derivative davon und seine verwendung |
US6114133A (en) | 1994-11-14 | 2000-09-05 | Elan Pharmaceuticals, Inc. | Methods for aiding in the diagnosis of Alzheimer's disease by measuring amyloid-β peptide (x-≧41) |
US7427392B1 (en) | 1994-11-14 | 2008-09-23 | Elan Pharmaceuticals, Inc. | Methods for aiding in the diagnosis of alzheimer's disease by measuring amyloid-β peptide (x-≧41) and tau |
US5786180A (en) | 1995-02-14 | 1998-07-28 | Bayer Corporation | Monoclonal antibody 369.2B specific for β A4 peptide |
DE60114157T2 (de) | 2000-02-21 | 2006-06-29 | Pharmexa A/S | Verfahren zur herabregulierung von amyloid |
US20050227941A1 (en) * | 2001-12-17 | 2005-10-13 | Karen Duff | Sequestration of ass in the periphery in the absence of immunomodulating agent as a therapeutic approach for the treatment or prevention of beta-amyloid related diseases |
US7380724B2 (en) | 2002-07-01 | 2008-06-03 | Sony Ericsson Mobile Communications Ab | Entering text into an electronic communication device |
JP4252956B2 (ja) | 2002-10-29 | 2009-04-08 | Hoya株式会社 | 化学強化用ガラス、情報記録媒体用基板、情報記録媒体及び情報記録媒体の製造方法 |
JP4252954B2 (ja) | 2004-12-02 | 2009-04-08 | インターナショナル・ビジネス・マシーンズ・コーポレーション | 情報処理装置、情報処理装置のパワーマネージメント方法、およびそのためのプログラム |
-
1995
- 1995-06-06 US US08/466,554 patent/US7427392B1/en not_active Expired - Fee Related
- 1995-11-13 JP JP51622096A patent/JP3634375B2/ja not_active Expired - Lifetime
- 1995-11-13 EP EP04077711A patent/EP1491889A3/de not_active Withdrawn
- 1995-11-13 PT PT95939892T patent/PT792458E/pt unknown
- 1995-11-13 ES ES95939892T patent/ES2230551T3/es not_active Expired - Lifetime
- 1995-11-13 WO PCT/US1995/014659 patent/WO1996015452A1/en active IP Right Grant
- 1995-11-13 AT AT95939892T patent/ATE278957T1/de active
- 1995-11-13 DK DK95939892T patent/DK0792458T3/da active
- 1995-11-13 EP EP95939892A patent/EP0792458B1/de not_active Revoked
- 1995-11-13 DE DE69533623T patent/DE69533623T2/de not_active Expired - Lifetime
- 1995-11-13 CA CA002205359A patent/CA2205359C/en not_active Expired - Lifetime
- 1995-11-13 AU AU41544/96A patent/AU705907B2/en not_active Ceased
-
2003
- 2003-11-20 JP JP2003391483A patent/JP2004077499A/ja not_active Withdrawn
-
2004
- 2004-06-25 US US10/877,688 patent/US20040253643A1/en not_active Abandoned
- 2004-06-28 US US10/879,958 patent/US7811769B2/en not_active Expired - Fee Related
- 2004-10-12 US US10/964,484 patent/US7700309B2/en not_active Expired - Fee Related
Also Published As
Publication number | Publication date |
---|---|
US20040265920A1 (en) | 2004-12-30 |
CA2205359C (en) | 2006-07-04 |
AU705907B2 (en) | 1999-06-03 |
US7427392B1 (en) | 2008-09-23 |
CA2205359A1 (en) | 1996-05-23 |
ATE278957T1 (de) | 2004-10-15 |
DE69533623T2 (de) | 2006-03-02 |
DK0792458T3 (da) | 2005-01-31 |
EP1491889A3 (de) | 2005-04-06 |
JPH10509797A (ja) | 1998-09-22 |
JP3634375B2 (ja) | 2005-03-30 |
US7811769B2 (en) | 2010-10-12 |
PT792458E (pt) | 2005-02-28 |
EP0792458A1 (de) | 1997-09-03 |
EP0792458B1 (de) | 2004-10-06 |
ES2230551T3 (es) | 2005-05-01 |
WO1996015452A1 (en) | 1996-05-23 |
US20040253643A1 (en) | 2004-12-16 |
EP1491889A2 (de) | 2004-12-29 |
US20050069968A1 (en) | 2005-03-31 |
JP2004077499A (ja) | 2004-03-11 |
EP0792458A4 (de) | 1999-04-07 |
US7700309B2 (en) | 2010-04-20 |
AU4154496A (en) | 1996-06-06 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DE69533623D1 (de) | Verfahren zur unterstützung der diagnose der alzheimerschen krankheit durch messung der amyloid-beta-peptide(x groesser als oder gleich 41) und tau | |
Kokmen et al. | Is the incidence of dementing illness changing? A 25‐year time trend study in Rochester, Minnesota (1960‐1984) | |
SE9401351D0 (sv) | A method for diagnosis | |
DE69707266D1 (de) | Verfahren zum überwachen der gesundheit eines patienten durch messen und vorhersage des glucosespiegels einer blutprobe des patienten | |
ATE160875T1 (de) | Verfahren zum nachweis und/oder zur bestimmung und/oder zur isolierung von apoptotischen zellen in oder aus einer probe | |
DE69131681D1 (de) | Rechnergestütztes System zur Diagnose für medizinischen Gebrauch | |
ATE447016T1 (de) | Prüfung und modell für alzheimers-krankheit | |
EP1102198A3 (de) | Automatisiertes Sammlungs und Analyse- Patienten, Pflegesystem und Verfahren zur Diagnose und Ueberwachung von Ateminsuffizienzen und dessen Ergebnisse | |
NO950636L (no) | Metode for måling | |
ATE447357T1 (de) | Verfahren und vorrichtung zur frühdiagnose von subakuten, aber möglicherweise tödlichen krankheiten | |
EP1226783A3 (de) | Verfahren und medizinisches System zur Überwachung eines an Epilepsie leidenden Patienten | |
Boston | Initial in vitro evaluation of DIAGNOdent for detecting secondary carious lesions associated with resin composite restorations. | |
US20060205024A1 (en) | Method to diagnose and evaluate progression of Alzheimer's disease | |
Price et al. | Allergy to rabbits: II. Identification and characterization of a major rabbit allergen | |
JPH02243951A (ja) | 鉄筋コンクリート内部の鋼材の腐食を診断するための方法 | |
Morimoto et al. | The functional evaluation of salivary glands using dynamic MR sialography following citric acid stimulation: a preliminary study | |
Hinrichs et al. | A comparison of 3 systems for quantifying gingival crevicular fluid with respect to linearity and the effects of qualitative differences in fluids | |
JP4735503B2 (ja) | 腹膜機能マーカー、その分析方法およびその用途 | |
Mutti et al. | Reference values for early markers of renal damage | |
LU86654A1 (de) | Verfahren und vorrichtung zum auffinden von zellaesionen | |
DE60043146D1 (de) | Immuntest für humanes Medullasin und Verfahren zur Diagnose von multipler Sklerose | |
Anyaiwe | Pathology and Neuroimaging for Alzheimer’s Disease | |
RU2159576C2 (ru) | Способ оценки величины воздействия на организм человека различных нагрузок | |
Cox et al. | Serum creatine kinase studies in mandibular pain dysfunction | |
Le Gall | Scoring systems and prognostic indexes |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
8363 | Opposition against the patent |